Intellectual Disability is a common and heterogeneous disorder characterized by limitations in intellectual functioning and adaptive behaviour, whose molecular mechanisms remain largely unknown. Among the numerous genes found to be involved in the pathogenesis of intellectual disability, 10% are located on the X-chromosome. We identified a missense mutation (c.236 C > G; p.S79W) in the SYN1 gene coding for synapsin I in the MRX50 family, affected by non-syndromic Xlinked intellectual disability. Synapsin I is a neuronal phosphoprotein involved in the regulation of neurotransmitter release and neuronal development. Several mutations in SYN1 have been identified in patients affected by epilepsy and/or autism. The S79W mutation segregates with the disease in the MRX50 family and all affected members display intellectual disability as sole clinical manifestation. At the protein level, the S79W Synapsin I mutation is located in the region of the B-domain involved in recognition of highly curved membranes. Expression of human S79W Synapsin I in Syn1 knockout hippocampal neurons causes aberrant accumulation of small clear vesicles in the soma, increased clustering of synaptic vesicles at presynaptic terminals and increased frequency of excitatory spontaneous release events. In addition, the presence of S79W Synapsin I strongly reduces the mobility of synaptic vesicles, with possible implications for the regulation of neurotransmitter release and synaptic plasticity. These results implicate SYN1 in the pathogenesis of non-syndromic intellectual disability, showing that alterations of synaptic vesicle trafficking are one possible cause of this disease, and suggest that distinct mutations in SYN1 may lead to distinct brain pathologies.
Introduction
The term Intellectual Disability (ID) refers to a heterogeneous group of disorders with onset during the developmental period and characterized by deficits in intellectual functions and adaptive behaviours that impact on the conceptual, social and practical domains of the person (1) . Syndromic and non-syndromic ID can be distinguished, depending on whether patients display multi-organ involvement or intellectual impairment is the only clinical manifestation, respectively. The prevalence estimates of ID are highly variable, due to the huge phenotypic heterogeneity and difficulties in patient stratification, but many studies agree on a value of approximately 1% in the overall population (2) . Comorbidity with other cognitive disorders is often observed, particularly with autism spectrum disorder (ASD), as it is estimated that 40% of ID patients are also affected by ASD and, conversely, that 50-85% of ASD patients show ID (3, 4) .
Genetic causes probably account for the majority of moderate-to-severe ID cases; still, many patients lack a molecular diagnosis. Genetic defects include large chromosomal aberrations, submicroscopic deletions/duplications, as well as monogenic defects and single-nucleotide variations (5, 6) . The identification of individual genes involved in ID is continuously evolving. The exact number of ID genes varies according to the developmental disorders that are taken into consideration, but recent reports list >800 protein-coding genes involved in syndromic and non-syndromic ID, of which more than 10% are X-linked (7) . Many of these genes converge on few common functional networks, as many ID proteins participate in the same cellular and molecular processes, including neurogenesis, neuronal migration, synapse formation and functioning (8). Several ID causative mutations have been found in genes coding for proteins involved in synaptic vesicle (SV) recycling at the presynaptic terminal, such as aGDI (Rab GDP-dissociation inhibitor alpha), RAB3GAP (Rab3 GTPase-activating protein) or MUNC-18 (9) (10) (11) (12) (13) .
Nonsense and missense mutations in the SYN1 and SYN2 genes, encoding the presynaptic proteins Synapsin (Syn) I and II, have been identified in patients affected by epilepsy in combination with learning disability (14) or ASD (15, 16) . Synapsins are a family of three neuronal proteins (SynI, SynII and SynIII), which display redundant, as well as distinct, structural and functional features (17) . The most characterized member is SynI, a protein that reversibly associates with the surface of SVs and the actin cytoskeleton in a phosphorylation-dependent manner. By virtue of these properties and of its ability to oligomerize, SynI mediates the clustering of SVs in the presynaptic terminal, regulates the number of SVs available for exocytosis and facilitates the postdocking steps of exocytosis (17) . Through this mechanism, SynI directly modulates neurotransmitter release and finely tunes synaptic strength and plasticity (18) . In addition, SynI plays a role in synaptogenesis and neurite outgrowth during neuronal development (19) .
We have identified a novel missense mutation in the SYN1 gene (c.236 C > G, S79W) in the MRX50 family, a European family affected by non-syndromic X-linked ID (XLID) with no clinical history of epilepsy or ASD (20) . The mutation causes the substitution of a phylogenetically conserved Serine residue with a Tryptophan, with possible severe implications for the folding and function of the protein. We characterized the effects of S79W SynI expression in heterologous HeLa cells and in Syn1 knock-out (KO) hippocampal neurons in culture. We found that S79W SynI promotes the formation of aberrant perinuclear accumulations of small clear vesicles. In addition, in neurons it affects SV clustering at presynaptic terminals, spontaneous SV release and SV mobility. These data support a causative role of this mutation and the derived functional alterations of synaptic function in determining the ID phenotype in the MRX50 family.
Results
Identification of the c.236 C > G (p.S79W) mutation in the MRX50 family Several SYN1 mutations have been described in families affected by epilepsy and/or ASD, in some cases associated with cognitive disability (14, 15) . We therefore investigated whether mutations in this gene, located on the X chromosome, might be associated with a primary cognitive phenotype and XLID. In collaboration with the Euro-MRX Consortium (http://euromrx.com; date last accessed September 15, 2017), we selected 12 families mapped by linkage analysis to the SYN1 locus, Xp11.23 (Supplementary Material, Table  S1 ) (21) . These 12 families were screened for the presence of mutations in the SYN1 gene by direct sequencing of the entire coding region (13 exons including splicing sites), 5'/3' untranslated regions (UTR) and part of the proximal promoter region in one proband/ family. The sequence obtained was compared with the reference human genomic sequence available in the NCBI (accession number: NG_008437.1) and Ensembl (accession number: ENSG00000008056) databases. The screening resulted in the identification of a point mutation in the coding region of the gene in one of the probands analysed, belonging to the L027 family (see Supplementary Material, Table S1 ). This family, also annotated as MRX50, displayed a lod score >2 with the SYN1 locus in the linkage analysis. The mutation consisted in a C-to-G transition in the 1 st exon of the SYN1 gene (c.236 C > G) (Fig. 1A) . The presence of the c.236 C > G mutation was assessed in the rest of the MRX50 family. All affected males whose DNA was available carried the mutation, which was absent in healthy members and present in heterozygous state in an obligate carrier female. In addition, the mutation was absent in 151 healthy control males analysed, as well as in dbSNP (22) . The complete pedigree of the family, clearly indicating a X-linked mode of inheritance, is shown in Figure 1B . The clinical characterization of the MRX50 patients has been previously published (20) . Patients were described as affected by a moderate to severe ID, appearing at approximately 6 years of age and requiring special education. The obligate carrier female IV-11 had a reduced intelligence. Patients showed no other phenotypic abnormalities and their neurological profile was normal, with no epileptic seizures reported. The pathological phenotype was therefore classifiable as a non-syndromic form of XLID. This was also confirmed by our evaluation of the only surviving patient of the family (V-19), performed in 2011. This man was 81 years old and lived in a nursing home. He had a moderate ID, severe perseveration and echolalia, but no other stereotypies, dysmorphisms or phenotypic abnormalities (normal testis volume and head size).
From the medical files of the family, neither the patient nor any of the affected males was ever reported to have experienced seizures. The patient died in 2012, and no new affected males were born because most females were appropriately counselled. At the protein level, the nucleotide transition identified results in the substitution of Serine 79 (Ser/S, codified by a TCG codon) with a Tryptophan (Trp/W, TGG codon). Ser-79 lies in domain B of SynI (Fig. 1C) . This domain contains a membrane curvature sensor motif named amphipathic lipid packing sensor (ALPS), which facilitates SynI association with SVs (23) . The S79W substitution may strongly impact on the folding of the motif. Indeed, the bioinformatics tool PolyPhen-2 (24) predicted a high probability of damage for the S79W substitution on SynI protein structure, giving maximal scores (0.998-1) with two different false positive rate thresholds. In addition, Ser-79 lies in very close proximity to two important phosphorylation sites (Ser-62 and Ser-67), which are targeted by mitogen-activated protein kinase (MAPK) and modulate SynI binding to SVs and actin (25, 26) , and to an O-glycosylation site (Thr-87) that regulates SynI localization to synapses (27) . Thus, the S79W substitution might also affect the accessibility of these residues to MAPK and N-acetylglucosamine transferase, and derange SynI post-translational modifications.
The phylogenetic alignment of the SynI protein sequence showed that Ser-79 is highly conserved among species from Aplysia to human (Fig. 1D) , raising the possibility that this site is evolutionarily important for SynI function. This residue has never been described as being post-translationally modified. The bioinformatics tools NetOGlyc 4.0 (28) and NetPhos 3.1 (29) did not predict Ser-79 as a possible target of O-glycosylation or phosphorylation, aside from a barely significant prediction as substrate for cyclin-dependent kinase 1 (Cdk1). Genomic DNA was available and analysed for members indicated with E (Eþ: mutation carrier; E-: non carrier). The index was V-19. Female IV-11 is an obligate carrier (Eþ/-), as she had both affected and unaffected sons. at the bottom, with 'asterisk' being residue identity in all species, 'colon' conservation between strongly similar groups of amino acids, and 'dot' conservation between weakly similar residues. Ser-79 is indicated with a red arrowhead.
S79W SynI promotes the formation of perinuclear accumulations of small clear vesicles in HeLa cells and hippocampal neurons
In order to study the effects of the S79W mutation on SynI structure and function, we produced plasmid constructs encoding either the WT or the S79W human SynI protein fused with the red fluorescent protein mCherry. When transfected in HeLa cells grown in culture, the S79W mutant protein formed large perinuclear aggregates that were never observed in WT SynI-transfected cells. Interestingly, the expression of a pseudocontrol SynI mutant bearing a more conservative residue substitution (Ser-to-Ala, S79A) did not induce the formation of aggregates and the protein appeared diffused in the cell cytoplasm like the WT SynI ( Fig. 2A) . To exclude that this effect was due to the fluorescent tag used, we produced FLAG-tagged and untagged WT and mutant human SynI, as well as untagged WT and mutant murine SynI plasmidic constructs. In all cases, the aggregation phenotype was observed only with the S79W SynI variant (Supplementary Material, Fig. S1 ). Thus, we decided to use the mCherry-tagged constructs for all subsequent experiments.
The expression levels of S79W SynI, as assessed through Western blotting in HeLa cells (Fig. 2B) , were identical to those of the WT and S79A isoforms, suggesting that the mutation does not affect protein synthesis or stability. Aggregate solubility in Triton-X100 was tested through Western blot analysis of total lysates, supernatants and Triton-insoluble pellets from transfected HeLa cells. WT and S79W SynI were largely extracted in the Triton-soluble fraction (Fig. 2C) . On the contrary, the aggregates formed by the W356X SynI variant -the first SYN1 mutation identified in epileptic patients (14)-were virtually insoluble, as previously reported (30) .
At the ultrastructural level, HeLa cells expressing S79W SynI were characterized by the presence of large clusters of small clear vesicles, which were never observed in cells transfected with the WT SynI isoform (Fig. 2D) . Interestingly, when HeLa cells were co-transfected with a construct coding for the transmembrane SV protein synaptophysin tagged with the enhanced cyan fluorescent protein (Syp-ECFP), Syp was completely sequestered in S79W SynI aggregates (Fig. 3) . Conversely, in cells transfected with WT SynI, Syp-ECFP showed a punctate staining that only rarely co-localized with SynI. S79W SynI might therefore be able to promote the accumulation of vesicular organelles intrinsically competent for sorting SV proteins in heterologous cells that do not endogenously express them.
Next, we tested the expression of S79W SynI in primary neuronal cells. High efficiency of transduction was achieved through lentiviral infection. In order to recapitulate the neurobiological conditions of the MRX50 patients and avoid possible artefacts caused by SynI overexpression, all experiments in primary neuronal cells were performed using Syn1 KO neurons in which we reintroduced either WT or S79W SynI. Hippocampal neurons were infected at 10 DIV, and analysed at 17 DIV. The expression levels of WT and S79W SynI were comparable, as assessed through Western blotting (Fig. 4A ). In analogy with what observed in HeLa cells, also in neurons the S79W SynI protein formed large somatic accumulations that co-localized with the SV marker vesicular glutamate transporter 1 (VGLUT1) and that were absent in cells transduced with WT SynI (Fig. 4B ). Electron microscopy analysis showed that the expression of S79W SynI was able to cause the accumulation, in the neuronal somata, of small clear vesicles with homogeneous diameter (40-60 nm, consistent with SV dimension) (Fig. 4Ca) . Such abnormal clusters of vesicles were also observed in other cellular districts, as they appeared to be aberrantly transported in dendrites (Fig. 4Cb ). This kind of structures was never visible in neurons transduced with WT SynI (Fig. 4Cc) . Interestingly, in both HeLa cells and neurons, the somatic accumulations of small clear vesicles were often in close apposition to the Golgi cisternae, raising the possibility that S79W SynI is able to promote an aberrant production of vesicles (possibly, SV precursor vesicles in neurons) through the budding from Golgi membranes (Supplementary Material, Fig. S2 ). S79W SynI was not completely sequestered in perinuclear accumulations, but was still able to reach bona fide presynaptic terminals, as the number of puncta positive for the presynaptic protein Bassoon and for SynI was comparable in neurons expressing either S79W or WT SynI (Fig. 4D ).
S79W SynI expression does not affect early neuronal development
Syns have been shown to have a role in the first stages of neuronal development (31) . We tested the effects of S79W SynI expression on neurite elongation and axonal branching in cultured Syn1 KO hippocampal neurons. To this aim, neurons were electroporated at 0 DIV with plasmidic constructs coding for either mCherry-tagged WT SynI, S79W SynI or mCherry alone. Cells were fixed at 1.5 DIV and stained for bIII-tubulin, which decorates the entire neuronal profile. The number and length of neurites of mCherry-positive isolated cells were measured for each condition. The analysis failed to reveal defects in total neurite length, axonal length or number of axonal branches in neurons expressing S79W SynI compared with neurons expressing either WT SynI or mCherry ( Fig. 5A-D ).
S79W SynI expression increases the frequency of miniature excitatory postsynaptic currents and the number of synaptic vesicles at presynaptic terminals
Given the well-established role of SynI in the regulation of neurotransmitter release at mature presynaptic terminals, we evaluated the effects of S79W SynI on basal synaptic transmission in mature neurons. Patch-clamp recordings of miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs) were performed in Syn1 KO hippocampal neurons transduced with lentiviruses coding for either mCherry-tagged WT SynI, S79W SynI or mCherry alone. Neurons were infected at 10 DIV and analysed at 16-17 DIV. The expression of S79W SynI caused a significant increase in the frequency of mEPSCs as compared with neurons expressing either WT SynI or mCherry alone ( Fig. 6A and B) . The amplitude of mEPSCs was unaffected in all cases (Fig. 6C ). The input resistance (mCherry: 149.85 6 8.99 mX; WT SynI: 139.15 6 8.85 mX; S79W SynI: 126.19 6 5.65 mX mean 6 SEM) and resting potential (mCherry: -59.37 6 1.04 mV; WT SynI: -61.16 6 1.18 mV; S79W SynI: -60.6 6 0.90 mV mean 6 SEM) were not statistically different under the three conditions analysed, indicating that the passive properties of the cells were not altered by the expression of S79W SynI. Concerning GABAegic transmission, mIPSC frequency and amplitude were not significantly different in neurons expressing either mCherry-tagged WT SynI, S79W SynI or mCherry alone ( Fig. 6D-F) . These results indicate that the expression of S79W SynI leads to a marked presynaptic effect selectively in excitatory neurons.
In order to understand the cellular bases for the increased mEPSC frequency in S79W SynI expressing neurons, we performed transmission electron microscopy analyses. In excitatory terminals (i.e., asymmetric synapses), the density of SVs was significantly increased upon expression of S79W SynI as compared with WT SynI or mCherry ( Fig.7A and B ). In the same synapses, the mean nearest neighbour distance (MNND, i.e. the average distance between each vesicle and the nearest one) was significantly reduced (Fig. 7C) . No difference was observed in the number of SVs docked at the active zone (Fig. 7D ).
In inhibitory terminals (i.e., symmetric synapses), a slight but significant increase in the density of SVs was observed upon expression of S79W SynI ( Fig. 7E and F ). In the same synapses, MNND was significantly decreased (Fig. 7G ), whereas the number of docked SVs was unaffected (Fig. 7H) .
We also measured the density of excitatory synapses in neurons expressing either WT SynI, S79W SynI or mCherry by immunofluorescence analyses; no significant difference was apparent among the three conditions (Fig. 7I ).
S79W SynI reduces the mobile pool of synaptic vesicles
In hippocampal neurons, the distribution of mCherry-tagged S79W SynI along axons was markedly different from that of the WT protein: S79W SynI appeared to be highly clustered at presynaptic terminals, while WT SynI was more diffused along axons. In the presence of S79W SynI, also the staining for endogenous VGLUT1 appeared highly clustered, whereas it was more dispersed along axons in neurons expressing WT SynI. The presynaptic scaffolding protein Bassoon, instead, appeared punctate in both conditions (Fig. 8A) . To quantify this observation, we performed a mathematical analysis of SynI and VGLUT1 dispersion along axons (see Materials and Methods), by comparing neurons expressing WT or S79W SynI. The longitudinal, but not the transversal, dispersion of SynI and VGLUT1 signals was significantly reduced in neurons expressing S79W SynI as compared with neurons expressing WT SynI ( Fig. 8B-E) , indicating an increased clustering of SynI itself and of SVs at bona fide presynaptic terminals along the major axis of the axon. The differential clustering of S79W SynI and of endogenous SVs prompted us to hypothesize that the mobility of S79W SynI itself and of S79W SynI-coated SVs could be altered, with possible implications for the dynamic spatial organization of SV clusters. To test this hypothesis, we performed fluorescence recovery after photobleaching (FRAP) experiments in Syn1 KO hippocampal neurons expressing mCherry-tagged WT SynI or S79W SynI and a yellow fluorescent protein (YFP)-tagged version of the SV protein Syp. Photobleaching of SynI and Syp fluorescence was performed at single synaptic boutons and the dynamics of fluorescence recovery were monitored by timelapse imaging ( Fig. 8F and G) . The rate of SynI recovery after bleaching was biexponential and displayed comparable kinetics in S79W or WT SynI expressing neurons. The asymptotic value of recovery was 37 6 2% of the initial fluorescence for S79W SynI and 65 6 3% for WT SynI (P ¼ 0.0016, unpaired Student's t-test). The fast phase accounted for 23 6 4% of the asymptotic recovery for S79W SynI and 41 6 3% for WT SynI (P ¼ 0.024, unpaired Student's t-test). These results indicate that S79W and WT SynI have comparable mobility kinetics, but the high-mobility fraction is significantly smaller for S79W than for WT SynI. Similarly, the rate of Syp recovery after bleaching was biexponential and displayed comparable kinetics in S79W or WT SynI expressing neurons. The fast phase accounted for 25 6 0.6% of the asymptotic recovery for S79W SynI and 46 6 1% for WT SynI (P < 0.0001, unpaired Student's t-test). The weight of the fast component on the fluorescence recovery was 17 6 2% for S79W SynI and 12 6 2% for WT SynI (P ¼ 0.22, unpaired Student's t-test). These results indicate the presence of a significantly smaller pool of mobile SVs in presynaptic terminals expressing S79W SynI as compared with those expressing WT SynI, even though their mobility kinetics and their partitioning in fast-and slowly-moving pools were similar under the two conditions.
Discussion
We identified a novel missense mutation (c.236 C > G/p.S79W) in the SYN1 gene in the MRX50 family through a candidate-gene direct sequencing approach applied to a small number of families selected by linkage analysis. The family was classified as being affected by non-syndromic ID, i.e. characterized by a pure cognitive phenotype in the absence of other neurological deficits (20) . Several mutations in the SYN1 gene (p.Q555X, p.Q356X, p.A550T, p.T567A, p.A51G) have been identified in patients affected by epilepsy and/or autism (14, 15) . This is the first report indicating an involvement of SynI in the pathogenesis of nonsyndromic ID. Thus, the detailed characterization of the cellular and functional effects of this specific mutation is important to elucidate the mechanisms that specifically lead to isolated ID rather than epilepsy.
The identified mutation is a single nucleotide substitution (c.236 C > G), which causes an amino acid change at the protein level (S79W). Ser-79 resides in domain B of SynI and is perfectly conserved along evolution, suggesting that this residue is important for the biological properties of the protein. Domain B contains an evolutionary conserved motif named ALPS (32), which allows SynI to sense membrane curvature and facilitates its association with SVs (23) .
The ALPS peptide shows a random conformation in solution. The addition of highly curved liposomes mimicking the phospholipid composition and size (30-50 nm diameter) of SVs results in the folding of the motif as an amphipathic a-helix, while no folding is induced when the peptide is incubated with larger liposomes. Deletion of the ALPS motif hampers the ability of SynI to recognize highly curved membranes and to cluster SVs in vitro (23) . Ser-79 lies in the middle of the ALPS motif, which spans amino acids 69-96. We found that the expression of S79W SynI results in the accumulation of small clear vesicles in both HeLa cells and hippocampal neurons in culture. Thus, the S79W substitution seems to potentiate the ability of SynI to cluster SVs, possibly through an increased fitting to highly curved bilayers that could facilitate membrane budding processes. Interestingly, S79W SynI displays this aberrant property also when expressed in a heterologous system such as HeLa cells, indicating that the phenomenon does not require the presence of other synaptic interactors. The precise nature and origin of the small clear vesicles that accumulate in the perinuclear region of HeLa cells and hippocampal neurons expressing S79W SynI are difficult to figure out. We observed that these accumulations often reside in close proximity to the Golgi cisternae and that they colocalize with endogenous or exogenously expressed SV markers, suggesting that these organelles may represent SV precursors or intermediates deputed to SV protein sorting. Two possible explanations may be offered for these data: S79W SynI may be able either to promote the budding of new vesicles from Golgi membranes or to cluster pre-existing organelles.
ID is often associated with neurodevelopmental defects. Considering that synapsins have been linked to neuronal development and neurite extension (31), we evaluated whether S79W SynI interferes with these processes. The analysis of axonal and dendritic elongation in young hippocampal neurons expressing either WT or mutant SynI did not reveal any defect at the developmental stage analysed. Conversely, the Q555X mutation, identified in patients affected by epilepsy associated with learning disability and ASD, significantly impaired neurite extension when expressed in Syn1 KO hippocampal neurons (15) . This suggests that neurodevelopmental defects are not necessary to produce phenotypically isolated ID (not associated with epilepsy or ASD).
Despite the formation of somatic clusters, S79W SynI is transported to presynaptic terminals. We thus investigated the effects of the mutant protein on synaptic function and morphology in mature hippocampal neurons. Electrophysiological recordings showed that, as compared with neurons expressing WT SynI, neurons transduced with the S79W isoform have a higher frequency of mEPSCs, pointing to a presynaptic alteration. In agreement with this observation, the number of SVs clustered at presynaptic terminals in the presence of S79W SynI is significantly increased, while the number of synapses is unaffected by S79W SynI expression. Thus, S79W SynI probably increases spontaneous excitatory activity by positively affecting the number of SVs that are available for release in the excitatory terminal. Spontaneous inhibitory transmission is not affected by S79W SynI expression, although SV density is slightly increased also in these terminals. This different behaviour may be ascribed to the higher frequency of spontaneous events that is typical of GABAergic terminals. Thus, these terminals are less sensitive to small increases in the number of SVs available. It is also noteworthy that SynI plays distinct roles at excitatory and inhibitory terminals, since its ablation differentially affects glutamatergic and GABAergic transmission (33) . Indeed, an imbalance between excitation and inhibition has been postulated to be at the basis of the epileptic phenotype observed in Syn KO mice (18, 33, 34) , and possibly also in human patients bearing SYN1 mutations (35) . Interestingly, excitation/inhibition imbalance and hyperexcitability of neuronal networks have been recently described in another example of XLID, namely fragile X syndrome (36) (37) (38) (39) .
Finally, we found that S79W SynI displays a decreased dispersion along axons than WT SynI. Consistently, SV markers are more efficiently clustered at bona fide synaptic boutons when S79W SynI is expressed. This result is in agreement with the reduction of the MNND measured in electron micrographs of presynaptic terminals. Functionally, this effect may have important implications in the dynamic regulation of SV recruitment upon stimulation, as it is possible that S79W SynI bears a higher affinity for SV membranes and detaches less easily upon stimulus-driven phosphorylation. Along this line, FRAP experiments indicate that S79W SynI has a reduced basal mobility along axons, suggesting that it is probably more stably anchored to SVs in presynaptic terminals. SVs themselves display a reduced mobility when S79W SynI is expressed, in agreement with the idea that SVs are more stably packed at presynaptic terminals and are less prone to travel along axons.
Sharing of SVs-belonging to the so-called "superpool"-between adjacent synapses is a well-known phenomenon (40) (41) (42) , which participates in the modulation of synaptic strength and relative weight of each synapse as a functional basis for synaptic plasticity (43) . Synapsins have been proposed to participate in the regulation of the SV superpool by restricting SV lateral mobility. The ablation of the three Syn genes in fact increases SV mobility along axons (44, 45) . In our experiments, S79W SynI is even more efficient than WT SynI in limiting SV lateral mobility between synapses. This may underlie important defects in establishing synaptic plastic modifications when S79W SynI is expressed.
In conclusion, we identified the c.236 C > G/p.S79W mutation in SYN1 as causative for the non-syndromic ID of the MRX50 family. Accordingly, the in vitro characterization of S79W SynI clearly indicates that the mutation does not interfere with neurodevelopmental aspects, but perturbs spontaneous SV exocytosis, SV clustering and SV lateral mobility along axons. All these phenomena may severely impact on the dynamics of complex plasticity phenomena, thus affecting learning and memory and leading to the cognitive phenotype observed in MRX50 patients. The molecular and functional characteristics of the S79W SynI mutant are unique with respect to those exhibited by the identified SynI mutants associated with epilepsy and ASD. Future structure-function studies will be performed to identify which of the multiple SynI functions and molecular interactors are involved in the genesis of distinct phenotypes, i.e. epilepsy, ASD or ID.
Materials and Methods
Patients' selection and analysis of the SYN1 gene Twelve genomic DNA samples from males with XLID mapped to Xp11 were obtained from the repository of the European Mental Retardation Consortium in Nijmegen, The Netherlands. Control DNAs were from a previous collection of adult European males (46) . For all individuals involved, the informed consent was obtained. The genomic organization of the SYN1 gene (GenBank NC_000023) was analysed based on the Ensembl database (accession number ENSG00000008056). Primers were designed in order to amplify fragments of the gene covering the entire coding sequence and the proximal promoter region (570 bp from the ATG). PCR amplification was performed with the GoTaq Flexi DNA polymerase (Promega, Madison, WI, USA), according to manufacturer's instructions, on a GeneAmp PCR System 9700 instrument (Applied Biosystems-Life technologies, Monza, Italy). PCR products were purified before sequencing with the Exo-SAP-IT (Exonuclease I and Shrimp Alkaline Phosphatase) reagent (USB, Cleveland, Ohio, USA). Direct sequencing was performed with the BigDye Terminator v1.1 Cycle Sequencing kit (BDv1.1, Applied Biosystems), with the same forward and reverse primers used for amplification and, when needed, with additional internal primers. The products of the sequencing reactions were purified with Sephadex G50 Superfine (GE Healthcare, Buckinghamshire, UK) and loaded onto MultiScreen HV 96-well plates (Millipore, Vimodrone, Italy). Samples were analysed in an ABI-3730 DNA Analyzer (Applied Biosystems). Sequences were manually verified through alignment with the reference sequence using ClustalW and BLASTN. A full list of primers used is reported in Supplementary Material, Table S2 . The mutation identified (c.236 C > G/S79W) has been submitted to the LSDB database (https://databases.lovd.nl/shared/genes/ SYN1; date last accessed September 15, 2017).
Animals
Mice were housed under constant temperature (22 6 1 C) and humidity (50%) conditions with a 12 h light/dark cycle, and were provided with food and water ad libitum. Syn1 KO mice (47) were used for generating primary neuronal cultures. All animal manipulations followed the guidelines established by the European Community Council (Directive 2010/63/EU of September 22nd, 2010) and were approved by the Institutional Animal Care and Use Committee (IACUC, permission number 467 and 565) of the San Raffaele Scientific Institute and by the Italian Ministry of Health. All efforts were made to minimize animal suffering.
Plasmids and lentiviral vectors
The mCherry-tagged human WT SYN1 (isoform Ia, NM_006950) construct was kindly provided by Dr. Anna Fassio (Department of Experimental Medicine, University of Genoa, Genoa, Italy) (15) . The FLAG-tagged version has been previously generated (30) . Non-tagged human WT SYN1 was obtained by subcloning the cDNA into the pCAG-IRES-tdTomato plasmid, kindly provided by Dr. Laura Cancedda (Istituto Italiano di Tecnologia, Genoa, Italy) (48) . The missense mutations c.236 C > G (S79W) and c.235 T > G (S79A) were inserted in the mCherry-and FLAGtagged WT SYN1 constructs by site-directed mutagenesis (QuikChange Lightning Mutagenesis Kit, Agilent Technologies) using the following primers: human S79W_for GTGGCTT CTTCTCGTGGCTGTCCAACGCG; human S79W_rev CGCGTTGG ACAGCCACGAGAAGAAGCCAC; human S79A_for GTGGCTTCTT CTCGGCGCTGTCCAACGCG; human S79A_rev CGCGTTGGACAG CGCCGAGAAGAAGCCAC. The pCMV6-mSyn1a plasmid, coding for mouse WT SynI, was purchased from Origene (Rockville, MD, USA). The same missense mutations (c.236 C > G and c.235 T > G) were inserted by site-directed mutagenesis (QuikChange Lightning Mutagenesis Kit, Agilent Technologies) using the following primers: mouse S79W_for GCGGCTTCTTC TCGTGGCTGTCTAACGCG; mouse S79W_rev CGCGTTAGACAG CCACGAGAAGAAGCCGC; mouse S79A_for GCGGCTTCTTCTCGG CGCTGTCTAACGCG; mouse S79A_rev CGCGTTAGACAGCGCCG AGAAGAAGCCGC. The plasmid coding for synaptophysin-ECFP (Syp-ECFP) has been previously generated (49) . Lentiviral vectors were produced by cloning the mCherry-tagged WT or S79W SynI or mCherry alone into the p743.pCCLsin.PPT.hPGK.GFP.Wpre vector provided by Dr. Luigi Naldini (San Raffaele Scientific Institute, Milan, Italy). Lentiviral vector for Syp-YFP has been previously generated (50) . Viral stocks were produced as previously described (44, 51) . All reagents used for cloning were from New England Biolabs (NEB, Ipswich, MA, USA).
Cell culture procedures
Primary neuronal cultures were prepared from the hippocampi of embryonic day 17.5 embryos from Syn1 KO mice of either sex, as previously described (44) . Neurons were plated on poly-L-lysine (0.1 mg/ml; Sigma-Aldrich, Milan, Italy)-coated 24 mm glass at a density of 150, 000 cells per coverslip, and maintained as a sandwich co-culture with astroglia in Modified Eagle's Medium (MEM; Invitrogen, Carlsbad, CA, USA) supplemented with 1% N2 supplement (Invitrogen), 2 mM glutamine (Invitrogen), 1 mM sodium pyruvate (Sigma-Aldrich, Milan, Italy), and 4 mM glucose, at 37 C in 5% CO 2 humidified atmosphere. For lentiviral transduction, coverslips were placed in a clean dish containing a mixture of fresh and conditioned medium, and were incubated overnight in the presence of viral stocks at a multiplicity of infection of 2-3. After transduction, neurons were returned to the original dishes and maintained in culture until analysis. For all experiments, neurons were infected at 10 DIV and analysed after one week, at 16-18 DIV.
Electroporation of neuronal cells was performed immediately after mechanical dissociation of the hippocampi with the Basic Primary Neurons Nucleofector Kit (Lonza, Basel, Switzerland) and the Amaxa Nucleofector Device (Amaxa Biosystems, Cologne, Germany), according to manufacturer's instructions (1 million cells and 3 lg of DNA/condition; O-05 program).
HeLa cells were grown in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen) supplemented with 10% foetal clone III serum (FCIII; Celbio, Pero, Italy), 1% glutamine and 1% penicillin/streptomycin (P/S; Invitrogen), at 37 C in 5% CO 2 humidified atmosphere.
Transient transfection of HeLa cells was performed with Lipofectamine-2000 (Invitrogen), following manufacturer's instructions.
Cell labelling, image acquisition and analysis
Immunofluorescence experiments were performed as previously described (44 . SynI and SV dispersion along axons was analysed by locating about 50 Bassoon puncta (range: 47-58) in each experiment, and adding up the images of the surrounding areas, centred on the highest intensity pixel of each spot ("centrepixel"). The resulting three-chromic images (red ¼ SynI, green ¼ Bassoon, blue ¼ VGLUT1) were displayed to offer a visual perception of the colocalization. The distribution of the proteins was analysed by measuring the light intensity in the three channels along the lines that crossed at the centre-pixel, parallel and orthogonal to the major axis of the neurite. To quantitatively compare the displacement of the markers, cumulative histograms were plotted and the median distance from the centrepixel was computed. To perform these analyses, original software was developed in Matlab R2011a environment (The MatWorks, Natick, MA).
Fluorescence recovery after photobleaching (FRAP)
Live neurons were imaged in KRH buffer (in mM: 130 NaCl, 
Western blotting
Neuronal cells were lysed with a buffer containing 1% sodium dodecylsulfate (SDS), 10 mM HEPES, 2 mM EDTA pH 7.4. Protein content was quantified with bicinchoninic acid assay (BCA, ThermoFisher). Laemmli buffer was added to a final 1X concentration (20 mM Tris pH 6.8, 2 mM EDTA, 2% SDS, 10% glycerol, 2% b-mercaptoethanol 0.01% bromophenol blue). Equal protein amounts were loaded on a polyacrylamide gel, subjected to standard SDS-PAGE, using a Standard Vertical Gel Electrophoresis unit (Hoefer, San Francisco, CA, USA), and transferred to a nitrocellulose membrane (Whatman GmbH, Dassel, Germany). Blocking of the membranes was performed in 5% milk-TBST (Tris-Base saline-Tween: 150 mM NaCl, 20 mM Tris-HCl pH 7.4, 0.05% Tween 20) for 1 h at room temperature (RT). Primary antibodies were appropriately diluted in 5% milk-TBST and incubated overnight at 4 C in a humidified chamber. Membranes were washed three times in TBST to eliminate primary antibody in excess. Secondary horseradish peroxidase (HRP)-conjugated antimouse and anti-rabbit antibodies (1: 10000, BioRad Cat#170-6516/ 6515 RRID: AB_11125547 RRID: AB_11125142, Hercules, CA, USA) were diluted in 5% milk-TBST and incubated for 1 h at RT. Membranes were washed three times in TBST to remove secondary antibodies in excess. Detection was performed with the enhanced chemiluminescence reaction (ECL; Amersham-GE Healthcare, Buckinghamshire, UK). Signals were visualized on ECL Hyperfilms (Amersham) and scanned with a desktop scanner (Epson Perfection V800 Photo) at 600 dpi. Primary antibodies used: mouse anti-Syn G143 (1: 5000, home-made) (52), rabbit anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase; 1: 10000, Cell Signaling Technology, Danvers, MA, USA); mouse anti-b-actin (1: 5000, Sigma-Aldrich).
Triton X-100 solubility of WT and S79W SynI was assessed as previously described (54) . Briefly, HeLa cells plated on 35 mm Petri dishes were transfected with FLAG-tagged constructs. After 48 h, cells were harvested and resuspended with 100 ll of a solution containing 10 mM Tris-HCl pH 7.4, 1 mM EDTA. The samples were then lysed with an equal volume of 2% Triton X-100 in the same Tris-EDTA buffer. Lysates were rotated on a wheel for 30 min at 4 C, then 50 ll were removed for the analysis of the total lysate, and the remaining lysates were centrifuged at 12, 000 g for 10 min. After withdrawal of the supernatants, the pellets were resuspended in 75 ll of 10 mM Tris-HCl pH 7.4, and treated with DNase (40 mg/ml final concentration) to digest any released DNA. The resuspended pellets were then brought to 150 ll, and equal volumes of the total lysates, pellets and supernatants were analysed by SDS-PAGE and Western blotting. All solutions contained a protease inhibitor cocktail (Sigma-Aldrich).
Electrophysiological recordings
Patch-clamp recordings were performed in an extracellular solution with the following composition (in mM): 130 NaCl, 5 KCl, . The resting potential was measured at I ¼ 0 in current clamp configuration, whereas input resistance was calculated in voltage clamp configuration by using the slope of the I/ V relationship of the steady state current measured at different hyperpolarizing voltage steps (from -100 to -70 mV). Infected cells were visualized using a LED-based illumination system (Cairn Research, Optoled, Faversham, UK). Only cells with an access resistance <20 MX were considered for the analysis. Access resistance was continuously monitored during the experiment and those cells in which access resistance was changed by more than 10% were rejected. The analysis of both mEPSC and mIPSC was performed with Mini analysis (Synaptosoft Inc., Fort Lee, NJ, USA).
Transmission electron microscopy
Primary hippocampal neurons were fixed with 1.3% glutaraldehyde in 66 mM sodium cacodylate buffer (pH 7.4), postfixed in 1% OsO4, 1.5% K 4 Fe(CN) 6 , 0.1 M sodium cacodylate, en bloc stained with 0.5% uranyl acetate, dehydrated and embedded in Epon. Ultrathin sections were contrasted with 2% uranyl acetate and Sato's lead solution (55) , observed with a LEO 912AB (Zeiss, Oberkochen, Germany) transmission electron microscope operated at 80 kV. Images were taken with a ProScan 2048x2048 pixel Slow-Scan CCD camera (ProScan, Lagerlechfeld, Germany) controlled by EsiVision 3.2 software (Soft-Imaging Software, Mü nster, Germany). Morphometric analysis of cross-section synaptic areas, total and docked SVs was performed in ImageJ. For the analysis of the spatial distribution of SVs, the position of each SV was located in ImageJ and the coordinates were transferred to Crimestat (Ned Levine; 2010, Houston, TX, USA) where the distance from the closest SV (mean nearest neighbour distance, MNND) was calculated.
Statistical analysis
Data were analysed using Microsoft Excel and Prism 5.0 software (GraphPad, La Jolla, CA, USA). Normality of data distributions was calculated using a Kolmogorov-Smirnov test. According to normality, data comparisons were computed using either unpaired Student's t-test or Mann-Whitney U-test in case of comparisons between two groups, and either one-way ANOVA followed by Tukey's multiple comparison test or Kruskal-Wallis test followed by the Dunn's multiple comparison test in case of comparisons between more than two groups.
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